Markers of insulin resistance in perimenopausal women with endometrial pathology

Ginekologia Polska

Volumn 84, Issue 11, 2013, Pages 922-929

  Kacalska Janssen, Olga ^a   Rajtar Ciosek, Agnieszka ^a   Zmaczyński, Andrzej ^a   Wyroba, Jakub ^a   Milewicz, Tomasz ^a   Krzyczkowska Sendrakowska, Magdalena ^a   Krzysiek, Józef ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Endometrial cancer; Endometrial polyp; Insulin resistance; Non Atypical endometrial hyperplasia

Indexed keywords

EID: 84893196772     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/1661     Document Type: Article

References (50)

1. Polotsky AJ, Santoro N. Uterine disease in midlife and beyond: the menopausal transition and postmenopause. In: The endometrium. Molecular, Cellular, and Clinical Perspectives. Ed. Aplin JD, Fazleabas AT, Glasser SR, Giudice L. London: Informa UK Ltd. 2008, 785-796.
2. Berstein LM, Kvatchevskaya JO, Poroshina TE, [et al.]. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol. 2004, 130, 687-693.
3. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000, 13, 295-308.
4. Giovannucci E. Nutrition, insulin, insulin-like growth factors, and cancer. Horm Metab Res. 2003, 35, 694-704.
5. Gottwald L, Chałubińska J, Moszyńska-Zielińska M, et al. Gruczolakorak endometrium typu endometrioidalnegoanaliza wartości prognostycznej wybranych parametrów klinicznych i histopatologicznych. Ginekol Pol. 2011, 82, 743-748.
6. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care. 1991, 14, 1132-1143.
7. IARC. Weight control and physical activity. IARC handbooks of cancer prevention. Lyon: IARC Press; 2002.
8. Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst. 2004, 96, 1635-1638.
9. Amant F, Moerman P, Neven P, et al.. Endometrial cancer. Lancet. 2005, 366, 491-505.
10. Calle EE, Rodriguez C, Walker-Thurmond K, et al.. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003, 348, 1625-1638.
11. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: A population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007, 16, 276-280.
12. Kaaks R., Lukanova A, Kurzer M. Obesity, Endogenous Hormones, and Endometrial Cancer Risk: A Synthetic Review. Cancer Epidemiol Biomarkers Prev. 2002, 11, 1531-1543.
13. Cobin RH. Medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract. 2006, 12, 315-337.
14. Aronne LJ. Classification of Obesity and Assessment of Obesity-Related Health Risks. Obesity Res. 2002, 10 (Suppl.2), 105S-115S.
15. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2007, 30 (suppl.1), S42-S47.
16. Matthews DR, Hosker JP, Rudenski AS, et al.. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in Man. Diabetologia. 1985, 8, 412-419.
17. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988, 57, 205-212.
18. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, et al.. Prediagnostic levels of C-peptide, IGF-I, IGFBP-1,-2 and-3 and risk of endometrial cancer. Int J Cancer. 2004, 108, 262-268.
19. Linkov F, Edwards R, Balk J, et al.. Endometrial hyperplasia, endometrial cancer and prevention: Gaps in existing research of modifiable risk factors. Eur J Cancer. 2008, 44, 1632-1644.
20. Hammond R, Johnson J. Endometrial hyperplasia. Curr Obstet Gyn. 2004, 14, 99-103.
21. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985, 56, 403-412.
22. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fetril Steril. 2003, 80, 1315-1324.
23. Ricci E, Moroni S, Parazzini F, et al.. Risk factors for endometrial hyperplasia: results from a case-control study. Int J Gynecol Cancer. 2002, 12, 257-260.
24. Van Bogaert L-J. Clinicopathologic findings in endometrial polyps. Obstet Gynecol. 1988, 71, 771-773.
25. Maguire M, Segars JH. Benign uterine disease: leiomyomata and benign polyps. In: The endometrium. Molecular, Cellular, and Clinical Perspectives. Ed. Aplin JD, Fazleabas AT, Glasser SR, Giudice LC. London: Informa UK Ltd, 2008, 797-812.
26. Reslova T, Tosner J, Resl M, et al.. Endometrial polyps. Arch Gynecol Obstet. 1999, 262,133-139.
27. Savelli L, De Iaco P, Santini D, et al.. Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps. Am J Obstet Gynecol. 2003, 188, 927-931.
28. Anastasiadis PG, Koutlaki NG, Skaphida PG, et al.. Endometrial polyps: prevalence, detection, and malignant potential in women with abnormal uterine bleeding. Eur J Gynaecol Oncol. 2000, 21, 180-183.
29. Shushan A, Revel A, Rojansky N. How often are endometrial polyps malignant? Gynecol Obstet Invest. 2004, 58,212-215.
30. Maia H, Maltez A, Athayde C, et al.. Proliferation profile of endometrial polyps in postmenopausal women. Maturitas. 2001, 40, 273-281.
31. Nappi L, Indraccolo U, Di Spiezio Sardo A, et al.. Are Diabetes, Hypertension, and Obesity Independent Risk Factors for Endometrial Polyps? J Minim Invas Gyn. 2009, 16, 157-162.
32. Reslova T, Tosner J, Resl M, et al.. Endometrial polyps: a clinical study of 245 cases. Arch Gynecol Obstet. 1999, 262,133-139.
33. Tjarks M, Van Voorhis BJ. Treatment of endometrial polyps. Obstet Gynecol. 2000, 96, 886-889.
34. Cohen MA, Sauer MV, Ketz M. Utilizing routine sonohysterography to detect intrauterine pathology before initiating hormone replacement therapy. Menopause. 1999, 6, 68-70.
35. IARC. Handbooks of Cancer Prevention, Vol. 6: Weight Control and Physical Activity. Lyon: International Agency for Research on Cancer. 2002, 6, 53-65.
36. Bergstorm A, Pisani P, Tenet V, et al.. Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001, 91, 421-430.
37. Giudice LC. Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract Res Clin Obstet Gynaecol. 2006, 20, 235-244.
38. Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol. 1998, 179, 6-12.
39. Troisi R, Potischman N, Hoover RN, et al.. Insulin and endometrial cancer. Am J Epidemiol. 1997, 146, 476-482.
40. Rutanen EM, Stenman S, Blum W, et al.. Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls. J Clin Endocrinol Metab. 1993, 77, 199-204.
41. Nagamani M, Hannigan EV, Dinh TV, et al.. Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. J Clin Endocrinol Metab. 1988, 67, 144-148.
42. Gamayunova VB, Bobrov Y, Tsyrlina EV, et al.. Comparative study of blood insulin levels in breast and endometrial cancer patients. Neoplasma. 1997, 44, 123-126.
43. Murphy LJ, Ghahary A. Uterine insulin-like growth factor-I: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev. 1990, 11, 443-453.
44. Rutanen EM, Nyman T, Lehtovirta P, et al.. Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors. Int J Cancer. 1994, 59, 307-312.
45. Vainio H, Bianchini F (eds.). Weight control and physical activity.. Lyon, France: IARC Press. 2002, vol 6, 1st ed.
46. Franks S, Kiddy DS, Hamilton-Fairley D, et al.. The role of nutrition and insulin in the regulation of sex hormone binding globulin. J Steroid Biochem Mol Biol. 1991, 39, 835-838.
47. Pasquali R, Vicennati V, Bertazzo D, et al.. Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group. Metabolism. 1997, 46, 5-9.
48. Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the Study of Insulin Resistance. Drugs. 1999, 58, 7-10.
49. Szoke E, Shrayyef MZ, Messing S, et al.. Effect of aging on glucose homeostasis. Accelerated deterioration of β-cell function in individuals with impaired glucose tolerance. Diabetes Care. 2008, 31, 539-543.
50. Reslova T, Tosner J, Resl M, et al.. Endometrial polyps: a clinical study of 245 cases. Arch Gynecol Obstet. 1999, 262, 133-139.